{"article_title": "Statin usefulness questioned, but patent expirations may ease pain", "article_keywords": ["pain", "expirations", "patent", "statins", "ease", "number", "drug", "sellers", "makers", "drugs", "questioned", "statin", "expired", "twitter", "usefulness"], "article_url": "http://blogs.marketwatch.com/health-exchange/2014/01/08/statin-usefulness-questioned-but-patent-expirations-may-ease-pain/", "article_text": "What should investors watch for as they consider that the usefulness of statin drugs in fighting \u201cbad cholesterol\u201d is being questioned?\n\nFor the most part, statins have outlived their usefulness for a number of high-profile drug makers. Patents on some of the biggest sellers in this space, including Pfizer Inc.\u2019s /quotes/zigman/238207/delayed /quotes/nls/pfe PFE superstar statin Lipitor, already have expired, opening the floodgates for a number of generic versions of these drugs.\n\nBloomberg Pfizer\u2019s patent already has expired on its statin, Lipitor.\n\nPatents long ago expired on other cholesterol-fighting drugs like Merck & Co.\u2019s /quotes/zigman/574389/delayed /quotes/nls/mrk MRK Zocor and Bristol-Myers Squibb\u2019s /quotes/zigman/220498/delayed /quotes/nls/bmy BMY Pravachol.\n\nMarketWatch\u2019s Elizabeth O\u2019Brien notes in her \u201cRetire Well\u201d column today that doctors are wondering whether the use of statins in fighting low-density lipoprotein, or LDL, many not be helpful in some situations.\n\nThat doesn\u2019t mean a chilling effect on statins would go unnoticed. Drug makers trying to invent better cholesterol drugs could be hurt. Some believe that new statins could be top sellers for years to come.\n\nFurther, companies like AstraZeneca /quotes/zigman/134653/delayed /quotes/nls/azn AZN , whose Crestor remains under patent, may see sales diluted.\n\nBut now that statins are widely circulated by a number of drug makers both under patented brands and generic offshoots, any pain that might be felt from new revelations will be spread throughout the industry.\n\nFollow Russ Britt on Twitter @russbrittmktw\n\nFollow Health Exchange on Twitter @MWHealthBlog\n\nMore health-care news from MarketWatch:\n\nForest shares soar after Aptalis purchase\n\nChart illustrates differences between states that love, hate Obamacare\n\nStaying on Obamacare sidelines helps UnitedHealth to new high", "article_metadata": {"article.created": "2014-01-08T13:02:40-05:00", "application-name": "MarketWatch.com", "twitter": {"domain": "Marketwatch.com", "description": "As the usefulness of statins come into question, investors should bear in mind that the cholesterol-fighting drugs already have outlived their usefulness for many drug makers.", "title": "Statin usefulness questioned, but patent expirations may ease pain", "url": "http://blogs.marketwatch.com/health-exchange/2014/01/08/statin-usefulness-questioned-but-patent-expirations-may-ease-pain/", "image": {"src": "http://s.wsj.net/public/resources/MWimages/MW-BS185_lipito_MG_20140108122529.jpg"}, "site": "MarketWatch", "card": "summary_large_image"}, "article.author": "Russ Britt", "article.section": "Markets", "keywords": "health care,Lipitor,Pfizer Inc.,pharmaceuticals,Statins", "article.headline": "Statin usefulness questioned, but patent expirations may ease pain", "msapplication-task": "name=SmartMoney;action-uri=http://www.smartmoney.com/;icon-uri=http://www.smartmoney.com/favicon.ico", "news_keywords": "health care,Lipitor,Pfizer Inc.,pharmaceuticals,Statins", "author": "Russ Britt", "article.page": "Health Exchange Blog", "description": "As the usefulness of statins come into question, investors should bear in mind that the cholesterol-fighting drugs already have outlived their usefulness for many drug makers.", "article.published": "2014-01-08T13:02:40-05:00", "ROBOTS": "noarchive, noodp", "msapplication-tooltip": "MarketWatch", "fb": {"url": "http://blogs.marketwatch.com/health-exchange/2014/01/08/statin-usefulness-questioned-but-patent-expirations-may-ease-pain/", "app_id": 283204329838}, "article": {"publisher": "https://www.facebook.com/marketwatch", "image_count": 2}, "og": {"site_name": "Marketwatch", "description": "As the usefulness of statins come into question, investors should bear in mind that the cholesterol-fighting drugs already have outlived their usefulness for many drug makers.", "title": "Statin usefulness questioned, but patent expirations may ease pain", "url": "http://blogs.marketwatch.com/health-exchange/2014/01/08/statin-usefulness-questioned-but-patent-expirations-may-ease-pain/", "image": {"width": 569, "identifier": "http://s.wsj.net/public/resources/MWimages/MW-BS185_lipito_MG_20140108122529.jpg", "height": 398}, "type": "article"}, "article.access": "free", "article.type": "Health Exchange", "article.id": "BL-MW243B-1824", "article.updated": "2014-01-08T13:02:40-05:00"}, "_id": "\"57477af36914bd0286fcbe54\"", "article_summary": "What should investors watch for as they consider that the usefulness of statin drugs in fighting \u201cbad cholesterol\u201d is being questioned?\nFor the most part, statins have outlived their usefulness for a number of high-profile drug makers.\nDrug makers trying to invent better cholesterol drugs could be hurt.\nBloomberg Pfizer\u2019s patent already has expired on its statin, Lipitor.\nBut now that statins are widely circulated by a number of drug makers both under patented brands and generic offshoots, any pain that might be felt from new revelations will be spread throughout the industry."}